Digital Storytelling Boosts Pediatric Influenza Vaccination Rates Despite Low Engagement: Insights from a Pilot Randomized Trial
Posted innews Pediatrics Public Health

Digital Storytelling Boosts Pediatric Influenza Vaccination Rates Despite Low Engagement: Insights from a Pilot Randomized Trial

A pilot randomized clinical trial reveals that text-based digital stories centered on community voices significantly improved influenza vaccination rates among children in Black communities, even though only 7% of caregivers viewed the narratives, highlighting a potential high-impact intervention for health equity.
Lifespan Management of ADHD: Landmark Umbrella Review Identifies Optimal Interventions and Critical Evidence Gaps
Posted innews Pediatrics Psychiatry

Lifespan Management of ADHD: Landmark Umbrella Review Identifies Optimal Interventions and Critical Evidence Gaps

A comprehensive BMJ umbrella review synthesizes evidence for ADHD interventions across the lifespan, confirming the efficacy of stimulants and non-stimulants in the short term while revealing a critical lack of high-certainty long-term data and introducing a new digital platform for shared clinical decision-making.
Real-World Implementation of RTS,S/AS01E Malaria Vaccine Reduces Severe Malaria by 58%: Evidence from the EPI-MAL-003 Phase 4 Study
Posted inInfectious Diseases news Pediatrics

Real-World Implementation of RTS,S/AS01E Malaria Vaccine Reduces Severe Malaria by 58%: Evidence from the EPI-MAL-003 Phase 4 Study

This interim analysis of the phase 4 EPI-MAL-003 study demonstrates that the RTS,S/AS01E malaria vaccine significantly reduces severe malaria, malaria-related hospitalizations, and all-cause hospitalizations in real-world clinical settings across Ghana, Kenya, and Malawi, supporting its widespread public health utility.
Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications
Posted inCritical Care Infectious Diseases news Pediatrics Public Health Respiratory

Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications

A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlights stewardship and surveillance priorities.
Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
Posted inInfectious Diseases news Pediatrics

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study

A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited reactions in adolescents.
Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study
Posted inHIV/AIDS news Pediatrics

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study

A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuations and comparable PK to historical pediatric data.
Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required
Posted inInfectious Diseases news Pediatrics Respiratory

Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required

A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12 months. Methodological limits temper causal inference.